Essential hypertension (EHT) has a genetic basis. Considering the pathological, physiological and biological mechanisms implicated in blood pressure regulation, many candidates have been listed as hypertension genes, of which the angiotensinogen gene (AGT) is weighed as the most promising one.
In 1992, Jeunemaitre et al. 1 first reported a linkage between genetic variants of AGT and EHT in humans, and found that the M235T mutation in exon 2 of AGT associated both elevated angiotensinogen concentrations and high hypertension risk. Later on, extensive association studies regarding genetic variants of AGT and EHT have been conducted, with inconsistent results. Several comprehensive meta-analyses, however, convincingly demonstrated a significant association between M235T and hypertension, with 235T allele conferring a combined relative risk of B1.2.
2, 3 Other polymorphisms in AGT such as A-20C and A-6G have also been shown to affect either blood pressure or gene expression. 4, 5 Thus, well characterizing the role of AGT may be a guide for elucidating the genetic makeup of EHT.
As a caveat, apparent inconsistency of results may reflect either a lack of statistical power due to the small sample size, or implication of different ethnic origins due to the evolutionary history or natural selection. To address this issue, we therefore conducted one of the largest genetic case-control studies to explore the contribution of three polymorphisms (A-20C, A-6G and M235T) of AGT to susceptibility for EHT, both individually and as haplotypes, in a Han Chinese population. The genetic homogeneity and geographic stability of this population, along with high prevalence of hypertension (16.8%) and low prevalence of treatment, provide an excellent opportunity for studying the genetic influence on hypertension. 6 Our study was based on a door-to-door crosssectional design. Details of this study population have been published. 6 Briefly, all subjects in this study are Han Chinese (pure pekingese) recruited from the Fangshan district in the southwest of Beijing. A total of 3045 subjects were recruited preliminarily, of whom we enrolled 1122 unrelated essential hypertensives with entry criteria as follows: (1) onset of age before 60 years; (2) mean systolic blood pressure (SBP) X140 mm Hg or mean diastolic blood pressure (DBP) X90 mm Hg; (3) free of secondary forms of hypertension through extensive clinical examination; (4) without any antihypertensive treatment. We matched 965 normotensives from the same area, according to the following criteria: (1) the enrolled age greater than 45 years; (2) SBP o130 mm Hg and DBP o85 mm Hg; (3) familial history without hypertension, hepatic disease, renal insufficiency and diabetes. Blood pressure was measured in the seated position after 10 min of rest using a mercury sphygmomanometer by experienced examiners. Afterwards, a detailed questionnaire was filled out and 5 ml blood sample was drawn from each subject for DNA extraction and biochemical examination. Body weight and height measurements were taken to calculate body mass index. This study was approved by the Ethics Committee of Chinese Academy of Medical Sciences/Peking Union Medical College and informed consent was obtained from each subject.
The genotypes of AGT polymorphisms were detected by polymerase chain reaction-restriction fragment-length polymorphism. With respect to the M235T polymorphism, the sequences of the forward and reverse primers were 5 0 -GATGCGCACA AGGTCCTG-3 0 and 5 0 -CAGGGTGCTGTCCACACTG GCTCGC-3 0 , respectively. Polymerase chain reaction was carried out in 25 ml reactions, including 10 pmol of each primer, 200 mmol l À1 dNTPs, 2.0 mmol l
À1
MgCl 2 , 2.5 mmol l À1 KCl and 0.5 U Taq DNA polymerase. Amplifications were done in a PTC-200 MJ Research Peltier Thermal Cycler (Bio-Rad Lab., MA, USA) for 30 cycles with denaturation at 941C for 1 min, annealing at 601C for 1 min and extension at 721C for 1 min. Restriction enzyme SfaNI (Promega, Beijing, China) recognized the amplified fragment (303 bp) when 235M is present (266 and 37 bp), and not when 235T is present. The A-20C and A-6G polymorphisms were genotyped according to a previous report. 5 Simple statistical analyses were performed using SAS 9.1.3 (Institute Inc., Cary, NC, USA). Differences in numerical data among the groups were calculated by the Student's t-test, and differences in genotype or allele distribution between hypertensives and normotensives, and Hardy-Weinberg equilibrium were analysed by w 2 -test. Continuous data were expressed as mean7s.d., and two-sided Po0.05 was considered statistically significant. EH/EH þ program 7 was employed to estimate haplotype frequencies along with the param and Ln(L). We compared haplotype frequencies between hypertensives and normotensives by w 2 -test from a series of 2 Â 2 contingency tables by combining other haplotypes. A probability value less than 0.00625 (0.05/8) was considered statistically significant after Bonferroni correction in multiple testing. Pairwise linkage disequilibrium coefficient was calculated with estimated haplotype frequencies using 2LD program. The extent of disequilibrium was expressed in terms of D 0 . For all polymorphisms analyzed, genotype distributions satisfied Hardy-Weinberg equilibrium in both groups. In single-locus analysis, the distributions of genotype/allele were significantly different between hypertensives and normotensives except for A-6G genotype distribution (P ¼ 0.0992) and M235T allele distribution (P ¼ 0.1467) ( Table 1) . Further, the A-20C and A-6G polymorphisms were significantly and independently associated with EHT with or without the adjustment of age, gender and body mass index (data not shown).
Haplotype-based analysis showed significant association with EHT (Po0.0001). The frequencies of haplotypes H 3 (P ¼ 0.0023) and H 6 (P ¼ 0.0001) were significantly higher, while the frequencies of H 2 (Po0.0001) and H 7 (Po0.0001) were significantly lower in hypertensives than that in normotensives (Table 1 Accumulating evidence including findings of elevation of plasma angiotensinogen concentrations and arterial blood pressure in mice duplicating the AGT, 8 strongly suggests that alteration in biological action of AGT is implicated in hypertension. Numerous linkage and association studies have proposed that genetic variants in AGT might contribute to variation of angiotensinogen concentrations and the risk for EHT in humans. 1, 9 Some, but not all, studies have identified genetic variants of AGT associated with susceptibility to EHT. Ethnic variety may account partly for genetic variety of many phenomena. Taking M235T as example, the 235T allele frequencies vary widely across different ethnic populations with a range from B35 to 90%, 1,10 which covers the frequency in the present study (B75%). Thus, it leaves open the possibility that hypertensive mechanisms might not be the same among people of different origin. In view of this, it is important to construct a database of polymorphisms related to EHT in each ethnic group.
Since genetic variation of AGT depends on the population structure and history, study of haplotype should prove useful for a more comprehensive analysis of association results. Haplotype was composed of different alleles, and so haplotype analysis could provide more information about the effect of genetic interaction, especially when these alleles have a synergistic effect. Our results suggested a protective effect for haplotypes H 2 and H 7 against the development of EHT, and that haplotypes H 3 and H 6 increased the susceptibility, even after the stringent Bonferroni correction. A previous study by Gu et al.
11 indicated that genetic variants in regulatory regions of AGT showed strong association with blood pressure reactivity. Further, another study examining the haplotypes of A-20C and A-6G suggested that haplotype frequencies in white men differed significantly between hypertensives and normotensives and the haplotype bearing À20A and À6A alleles was a risky combination for hypertension, 5 which was consistent with our results (data not shown). In addition, linkage patterns in our study were heterogeneous between hypertensives and normotensives, especially for A-20C and A-6G. Given the implication of natural selection in human evolution, haplotype structure that harbours contributing information might be dissimilar among populations with different disease-related conditions. Perhaps it seems reasonable to assume this way, but needs further proof.
It has been estimated that to generate robust data in complex diseases requires 41000 samples for each group 12 and our power estimates somewhat confirmed our capacity to do this. Moreover, our study population was enrolled in a populationbased study design differing from the hospital-based design, which might undertake the potentials of population admixture and stratification, and all genotype distributions satisfied Hardy-Weinberg equilibrium in both groups, which signified appropriate population selection. Together, these strengths strongly minimize the possibility of a chance finding in this study.
To sum up, our study demonstrated strong association of AGT polymorphisms with EHT both individually and interactively. However, because of the complex molecular interactions underlying the development of EHT, our results cannot be extrapolated directly to contributions of these polymorphisms to hypertensive patients, and thus reinforce the need for extensive replication and biological validation in different ethnic populations. 
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